100
Participants
Start Date
March 26, 2018
Primary Completion Date
May 30, 2021
Study Completion Date
May 30, 2021
Pembrolizumab
200 mg Q3W on Day 1 by IV infusion
Oxaliplatin
130 mg/m\^2 Q3W on Day 1 by IV infusion
TS-1
40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Cisplatin
60 mg/m\^2 Q3W on Day 1 by IV infusion
National Cancer Center Hospital East ( Site 0001), Kashiwa
National Hospital Organization Shikoku Cancer Center ( Site 0024), Matsuyama
Gunma Prefectural Cancer Center ( Site 0005), Ohta
Hokkaido University Hospital ( Site 0006), Sapporo
Hyogo Cancer Center ( Site 0016), Akashi
Kobe City Medical Center General Hospital ( Site 0015), Kobe
Ibaraki Prefectural Central Hospital ( Site 0018), Kasama
Kitasato University Hospital ( Site 0019), Sagamihara
Kanagawa Cancer Center ( Site 0003), Yokohama
Tohoku University Hospital ( Site 0023), Sendai
Kindai University Hospital ( Site 0013), Sayama
Osaka University Hospital ( Site 0010), Suita
Saitama Cancer Center ( Site 0004), Kitaadachi-gun
Shizuoka Cancer Center Hospital and Research Institute ( Site 0020), Sunto-gun
Jichi Medical University Hospital ( Site 0009), Shimotsuke
Chiba Cancer Center ( Site 0012), Chiba
National Hospital Organization Kyushu Cancer Center ( Site 0017), Fukuoka
Kyushu University Hospital ( Site 0014), Fukuoka
Gifu University Hospital ( Site 0021), Gifu
Kochi Health Sciences Center ( Site 0022), Kochi
Kumamoto University Hospital ( Site 0002), Kumamoto
Osaka International Cancer Institute ( Site 0011), Osaka
National Cancer Center Hospital ( Site 0025), Tokyo
Tokyo Metropolitan Komagome Hospital ( Site 0008), Tokyo
The Cancer Institute Hospital of JFCR ( Site 0007), Tokyo
Merck Sharp & Dohme LLC
INDUSTRY